Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook
December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11